THE IMPACT OF HOSPITAL PHARMACY SPECIALISATION ON THE PATIENTS’ OUTCOME: A LITERATURE REVIEW (submitted in 2019)
6ER-017
DIGITAL LITERACY OF PATIENTS IN A DAY HOSPITAL ONCOLOGY UNIT (submitted in 2019)
6ER-016
ECONOMIC VALUE OF UNUSED HIGH COST EXPERIMENTAL INFUSION DRUGS: A POTENTIAL SAVING FOR THE NATIONAL HEALTH SYSTEM (submitted in 2019)
6ER-015
RISKS OF PHARMACIST RECOMMENDED ANTIBIOTIC USE: GENERAL PUBLIC PERCEPTION (submitted in 2019)
6ER-014
EDUCATION OF PATIENTS RECEIVING OXYGEN THERAPY (submitted in 2019)
6ER-013
ENRICHED DEVELOPMENTAL BIOLOGY MOLECULAR PATHWAYS: IMPACT ON ANTIPSYCHOTIC INDUCED WEIGHT GAIN (submitted in 2019)
6ER-012
PERSISTENCE FOR DISEASE MODIFYING DRUGS FOR MULTIPLE SCLEROSIS (submitted in 2019)
6ER-011
REAL WORLD ADHERENCE TO MULTIPLE SCLEROSIS THERAPY (submitted in 2019)
6ER-010
THERAPEUTIC DRUG MONITORING OF TUMOUR NECROSIS FACTOR a INHIBITORS IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM A REAL WORLD SETTING (submitted in 2019)
6ER-009
TREATMENT PATTERNS IN MULTIPLE SCLEROSIS WITH DISEASE MODIFYING DRUGS (submitted in 2019)
6ER-008
STUDY OF THE USE OF DIMETHYL FUMARATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN A THIRD LEVEL HOSPITAL (submitted in 2019)
6ER-007
PERSISTENCE AND SAFETY OF ADALIMUMAB IN PSORIASIS (submitted in 2019)
6ER-006
DIGITAL LITERACY IN MULTIPLE SCLEROSIS (submitted in 2019)
6ER-005
EFFECTIVENESS OF OMALIZUMAB AND BEE VENOM IMMUNOTHERAPY COMBINATION: CASE REPORT (submitted in 2019)
6ER-004
PRELIMINARY CLINICAL RESPONSE OF RIBOCICLIB AS A SINGLE AGENT IN ADVANCED BREAST CANCER: IN SEARCH OF NEW THERAPEUTIC INDICATIONS (submitted in 2019)
